Top

Published in:

Open Access 01-04-2021 | Diabetic Retinopathy | Review

Hypoxia and hypoxia-inducible factors in diabetes and its complications

Authors: Sergiu-Bogdan Catrina, Xiaowei Zheng

Published in: Diabetologia | Issue 4/2021

Abstract

Hypoxia-inducible factors (HIFs) are the key regulators of oxygen homeostasis in response to hypoxia. In diabetes, multiple tissues are hypoxic but adaptive responses to hypoxia are impaired due to insufficient activation of HIF signalling, which results from inhibition of HIF-1α stability and function due to hyperglycaemia and elevated fatty acid levels. In this review, we will summarise and discuss current findings about the regulation of HIF signalling in diabetes and the pathogenic roles of hypoxia and dysregulated HIF signalling in the development of diabetes and its complications. The therapeutic potential of targeting HIF signalling for the prevention and treatment of diabetes and related complications is also discussed.

Graphical abstract

Available only for authorised users

Semenza GL (2019) Pharmacologic Targeting of Hypoxia-Inducible Factors. Annu Rev Pharmacol Toxicol 59:379–403. https://doi.org/10.1146/annurev-pharmtox-010818-021637CrossRefPubMed

Semenza GL (2017) A compendium of proteins that interact with HIF-1alpha. Exp Cell Res 356(2):128–135. https://doi.org/10.1016/j.yexcr.2017.03.041CrossRefPubMedPubMedCentral

Holmquist-Mengelbier L, Fredlund E, Lofstedt T et al (2006) Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell 10(5):413–423. https://doi.org/10.1016/j.ccr.2006.08.026CrossRefPubMed

Smythies JA, Sun M, Masson N et al (2019) Inherent DNA-binding specificities of the HIF-1alpha and HIF-2alpha transcription factors in chromatin. EMBO Rep 20(1). https://doi.org/10.15252/embr.201846401

Koyasu S, Kobayashi M, Goto Y, Hiraoka M, Harada H (2018) Regulatory mechanisms of hypoxia-inducible factor 1 activity: Two decades of knowledge. Cancer Sci 109(3):560–571. https://doi.org/10.1111/cas.13483CrossRefPubMedPubMedCentral

Arden GB, Sivaprasad S (2011) Hypoxia and oxidative stress in the causation of diabetic retinopathy. Curr Diabetes Rev 7(5):291–304CrossRef

Gu HF, Zheng X, Abu Seman N et al (2013) Impact of the hypoxia-inducible factor-1 alpha (HIF1A) Pro582Ser polymorphism on diabetes nephropathy. Diabetes Care 36(2):415–421. https://doi.org/10.2337/dc12-1125CrossRefPubMedPubMedCentral

Persson P, Palm F (2017) Hypoxia-inducible factor activation in diabetic kidney disease. Curr Opin Nephrol Hypertens 26(5):345–350. https://doi.org/10.1097/MNH.0000000000000341CrossRefPubMed

Sato Y, Endo H, Okuyama H et al (2011) Cellular hypoxia of pancreatic beta-cells due to high levels of oxygen consumption for insulin secretion in vitro. J Biol Chem 286(14):12524–12532. https://doi.org/10.1074/jbc.M110.194738CrossRefPubMedPubMedCentral

10.

Lee YS, Kim JW, Osborne O et al (2014) Increased adipocyte O2 consumption triggers HIF-1alpha, causing inflammation and insulin resistance in obesity. Cell 157(6):1339–1352. https://doi.org/10.1016/j.cell.2014.05.012CrossRefPubMedPubMedCentral

11.

Botusan IR, Sunkari VG, Savu O et al (2008) Stabilization of HIF-1alpha is critical to improve wound healing in diabetic mice. Proc Natl Acad Sci U S A 105(49):19426–19431. https://doi.org/10.1073/pnas.0805230105CrossRefPubMedPubMedCentral

12.

Catrina SB, Okamoto K, Pereira T, Brismar K, Poellinger L (2004) Hyperglycemia regulates hypoxia-inducible factor-1alpha protein stability and function. Diabetes 53(12):3226–3232. https://doi.org/10.2337/diabetes.53.12.3226CrossRefPubMed

13.

Marfella R, Esposito K, Nappo F et al (2004) Expression of angiogenic factors during acute coronary syndromes in human type 2 diabetes. Diabetes 53(9):2383–2391CrossRef

14.

Dodd MS, Sousa Fialho MDL, Montes Aparicio CN et al (2018) Fatty Acids Prevent Hypoxia-Inducible Factor-1alpha Signaling Through Decreased Succinate in Diabetes. JACC Basic Transl Sci 3(4):485–498. https://doi.org/10.1016/j.jacbts.2018.04.005CrossRefPubMedPubMedCentral

15.

Bento CF, Fernandes R, Ramalho J et al (2010) The chaperone-dependent ubiquitin ligase CHIP targets HIF-1alpha for degradation in the presence of methylglyoxal. PLoS One 5(11):e15062. https://doi.org/10.1371/journal.pone.0015062CrossRefPubMedPubMedCentral

16.

Katavetin P, Miyata T, Inagi R et al (2006) High glucose blunts vascular endothelial growth factor response to hypoxia via the oxidative stress-regulated hypoxia-inducible factor/hypoxia-responsible element pathway. J Am Soc Nephrol 17(5):1405–1413. https://doi.org/10.1681/ASN.2005090918CrossRefPubMed

17.

Thangarajah H, Yao D, Chang EI et al (2009) The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc Natl Acad Sci U S A 106(32):13505–13510. https://doi.org/10.1073/pnas.0906670106CrossRefPubMedPubMedCentral

18.

Ceradini DJ, Yao D, Grogan RH et al (2008) Decreasing intracellular superoxide corrects defective ischemia-induced new vessel formation in diabetic mice. J Biol Chem 283(16):10930–10938. https://doi.org/10.1074/jbc.M707451200CrossRefPubMedPubMedCentral

19.

Isoe T, Makino Y, Mizumoto K et al (2010) High glucose activates HIF-1-mediated signal transduction in glomerular mesangial cells through a carbohydrate response element binding protein. Kidney Int 78(1):48–59. https://doi.org/10.1038/ki.2010.99CrossRefPubMed

20.

Duscher D, Neofytou E, Wong VW et al (2015) Transdermal deferoxamine prevents pressure-induced diabetic ulcers. Proc Natl Acad Sci U S A 112(1):94–99. https://doi.org/10.1073/pnas.1413445112CrossRefPubMed

21.

Zhu Y, Wang Y, Jia Y, Xu J, Chai Y (2019) Roxadustat promotes angiogenesis through HIF-1alpha/VEGF/VEGFR2 signaling and accelerates cutaneous wound healing in diabetic rats. Wound Repair Regen 27(4):324–334. https://doi.org/10.1111/wrr.12708CrossRefPubMed

22.

Vinovskis C, Li LP, Prasad P et al (2020) Relative Hypoxia and Early Diabetic Kidney Disease in Type 1 Diabetes. Diabetes 69(12):2700–2708. https://doi.org/10.2337/db20-0457CrossRefPubMed

23.

Feng YZ, Ye YJ, Cheng ZY et al (2020) Non-invasive assessment of early stage diabetic nephropathy by DTI and BOLD MRI. Br J Radiol 93(1105):20190562. https://doi.org/10.1259/bjr.20190562CrossRefPubMedPubMedCentral

24.

Gilbert RE (2017) Proximal Tubulopathy: Prime Mover and Key Therapeutic Target in Diabetic Kidney Disease. Diabetes 66(4):791–800. https://doi.org/10.2337/db16-0796CrossRefPubMed

25.

Li R, Uttarwar L, Gao B et al (2015) High Glucose Up-regulates ADAM17 through HIF-1alpha in Mesangial Cells. J Biol Chem 290(35):21603–21614. https://doi.org/10.1074/jbc.M115.651604CrossRefPubMedPubMedCentral

26.

Garcia-Pastor C, Benito-Martinez S, Moreno-Manzano V, Fernandez-Martinez AB, Lucio-Cazana FJ (2019) Mechanism and Consequences of The Impaired Hif-1alpha Response to Hypoxia in Human Proximal Tubular HK-2 Cells Exposed to High Glucose. Sci Rep 9(1):15868. https://doi.org/10.1038/s41598-019-52310-6CrossRefPubMedPubMedCentral

27.

Sugahara M, Tanaka S, Tanaka T et al (2020) Prolyl Hydroxylase Domain Inhibitor Protects against Metabolic Disorders and Associated Kidney Disease in Obese Type 2 Diabetic Mice. J Am Soc Nephrol 31(3):560–577. https://doi.org/10.1681/ASN.2019060582CrossRefPubMedPubMedCentral

28.

Sousa Fialho MDL, Abd Jamil AH, Stannard GA, Heather LC (2019) Hypoxia-inducible factor 1 signalling, metabolism and its therapeutic potential in cardiovascular disease. Biochim Biophys Acta Mol Basis Dis 1865(4):831–843. https://doi.org/10.1016/j.bbadis.2018.09.024CrossRefPubMed

29.

Rahtu-Korpela L, Maatta J, Dimova EY et al (2016) Hypoxia-Inducible Factor Prolyl 4-Hydroxylase-2 Inhibition Protects Against Development of Atherosclerosis. Arterioscler Thromb Vasc Biol 36(4):608–617. https://doi.org/10.1161/ATVBAHA.115.307136CrossRefPubMed

30.

Cheng L, Yu H, Yan N, Lai K, Xiang M (2017) Hypoxia-Inducible Factor-1alpha Target Genes Contribute to Retinal Neuroprotection. Front Cell Neurosci 11:20. https://doi.org/10.3389/fncel.2017.00020CrossRefPubMedPubMedCentral

31.

Ekberg NR, Eliasson S, Li YW et al (2019) Protective Effect of the HIF-1A Pro582Ser Polymorphism on Severe Diabetic Retinopathy. J Diabetes Res 2019:2936962. https://doi.org/10.1155/2019/2936962CrossRefPubMedPubMedCentral

32.

Regazzetti C, Peraldi P, Gremeaux T et al (2009) Hypoxia decreases insulin signaling pathways in adipocytes. Diabetes 58(1):95–103. https://doi.org/10.2337/db08-0457CrossRefPubMedPubMedCentral

33.

Jiang C, Qu A, Matsubara T et al (2011) Disruption of hypoxia-inducible factor 1 in adipocytes improves insulin sensitivity and decreases adiposity in high-fat diet-fed mice. Diabetes 60(10):2484–2495. https://doi.org/10.2337/db11-0174CrossRefPubMedPubMedCentral

34.

Halberg N, Khan T, Trujillo ME et al (2009) Hypoxia-inducible factor 1alpha induces fibrosis and insulin resistance in white adipose tissue. Mol Cell Biol 29(16):4467–4483. https://doi.org/10.1128/MCB.00192-09CrossRefPubMedPubMedCentral

35.

Rahtu-Korpela L, Karsikas S, Horkko S et al (2014) HIF prolyl 4-hydroxylase-2 inhibition improves glucose and lipid metabolism and protects against obesity and metabolic dysfunction. Diabetes 63(10):3324–3333. https://doi.org/10.2337/db14-0472CrossRefPubMed

36.

Michailidou Z, Morton NM, Moreno Navarrete JM et al (2015) Adipocyte pseudohypoxia suppresses lipolysis and facilitates benign adipose tissue expansion. Diabetes 64(3):733–745. https://doi.org/10.2337/db14-0233CrossRefPubMed

37.

Gunton JE (2020) Hypoxia-inducible factors and diabetes. J Clin Invest 130(10):5063–5073. https://doi.org/10.1172/jci137556CrossRefPubMed

38.

Cheng K, Ho K, Stokes R et al (2010) Hypoxia-inducible factor-1alpha regulates beta cell function in mouse and human islets. J Clin Invest 120(6):2171–2183. https://doi.org/10.1172/JCI35846CrossRefPubMedPubMedCentral

39.

Stokes RA, Cheng K, Deters N et al (2013) Hypoxia-inducible factor-1alpha (HIF-1alpha) potentiates beta-cell survival after islet transplantation of human and mouse islets. Cell Transplant 22(2):253–266. https://doi.org/10.3727/096368912X647180CrossRefPubMed

40.

Gunton JE, Kulkarni RN, Yim S et al (2005) Loss of ARNT/HIF1beta mediates altered gene expression and pancreatic-islet dysfunction in human type 2 diabetes. Cell 122(3):337–349CrossRef

41.

Lalwani A, Warren J, Liuwantara D et al (2019) beta Cell Hypoxia-Inducible Factor-1alpha Is Required for the Prevention of Type 1 Diabetes. Cell Rep 27(8):2370–2384 e2376. https://doi.org/10.1016/j.celrep.2019.04.086CrossRefPubMedPubMedCentral

42.

Nomoto H, Pei L, Montemurro C et al (2020) Activation of the HIF1alpha/PFKFB3 stress response pathway in beta cells in type 1 diabetes. Diabetologia 63(1):149–161. https://doi.org/10.1007/s00125-019-05030-5CrossRefPubMed

43.

Cantley J, Selman C, Shukla D et al (2009) Deletion of the von Hippel-Lindau gene in pancreatic beta cells impairs glucose homeostasis in mice. J Clin Invest 119(1):125–135. https://doi.org/10.1172/JCI26934CrossRefPubMed

44.

Puri S, Cano DA, Hebrok M (2009) A role for von Hippel-Lindau protein in pancreatic beta-cell function. Diabetes 58(2):433–441. https://doi.org/10.2337/db08-0749CrossRefPubMedPubMedCentral

45.

Zehetner J, Danzer C, Collins S et al (2008) PVHL is a regulator of glucose metabolism and insulin secretion in pancreatic beta cells. Genes Dev 22(22):3135–3146. https://doi.org/10.1101/gad.496908CrossRefPubMedPubMedCentral

46.

Hoang M, Paglialunga S, Bombardier E, Tupling AR, Joseph JW (2019) The Loss of ARNT/HIF1beta in Male Pancreatic beta-Cells Is Protective Against High-Fat Diet-Induced Diabetes. Endocrinology 160(12):2825–2836. https://doi.org/10.1210/en.2018-00936CrossRefPubMedPubMedCentral

47.

Pichu S, Sathiyamoorthy J, Krishnamoorthy E, Umapathy D, Viswanathan V (2015) Impact of the hypoxia inducible factor-1alpha (HIF-1alpha) pro582ser polymorphism and its gene expression on diabetic foot ulcers. Diabetes Res Clin Pract 109(3):533–540. https://doi.org/10.1016/j.diabres.2015.05.014CrossRefPubMed

48.

Yamada N, Horikawa Y, Oda N et al (2005) Genetic variation in the hypoxia-inducible factor-1alpha gene is associated with type 2 diabetes in Japanese. J Clin Endocrinol Metab 90(10):5841–5847CrossRef

49.

Choudhry H, Harris AL (2018) Advances in Hypoxia-Inducible Factor Biology. Cell Metab 27(2):281–298. https://doi.org/10.1016/j.cmet.2017.10.005CrossRefPubMed

50.

Pang M, Li Y, Gu W, Sun Z, Wang Z, Li L (2020) Recent Advances in Epigenetics of Macrovascular Complications in Diabetes Mellitus. Heart Lung Circ. https://doi.org/10.1016/j.hlc.2020.07.015

51.

Hyvarinen J, Hassinen IE, Sormunen R et al (2010) Hearts of hypoxia-inducible factor prolyl 4-hydroxylase-2 hypomorphic mice show protection against acute ischemia-reperfusion injury. J Biol Chem 285(18):13646–13657. https://doi.org/10.1074/jbc.M109.084855CrossRefPubMedPubMedCentral

52.

Rojas DR, Tegeder I, Kuner R, Agarwal N (2018) Hypoxia-inducible factor 1alpha protects peripheral sensory neurons from diabetic peripheral neuropathy by suppressing accumulation of reactive oxygen species. J Mol Med (Berl) 96(12):1395–1405. https://doi.org/10.1007/s00109-018-1707-9CrossRef

53.

Zeinivand M, Nahavandi A, Zare M (2020) Deferoxamine regulates neuroinflammation and oxidative stress in rats with diabetes-induced cognitive dysfunction. Inflammopharmacology 28(2):575–583. https://doi.org/10.1007/s10787-019-00665-7CrossRefPubMed

54.

Dhillon S (2019) Roxadustat: First Global Approval. Drugs 79(5):563–572. https://doi.org/10.1007/s40265-019-01077-1CrossRefPubMed

Title: Hypoxia and hypoxia-inducible factors in diabetes and its complications
Authors: Sergiu-Bogdan Catrina
Xiaowei Zheng
Publication date: 01-04-2021
Publisher: Springer Berlin Heidelberg
Keywords: Diabetic Retinopathy
Insulins
Diabetic Retinopathy
Diabetic Nephropathy
Diabetic Foot
Hyperglycemia
Insulins
Published in: Diabetologia / Issue 4/2021
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-021-05380-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Graphical abstract

Please log in to get access to this content

Other articles of this Issue 4/2021

BMI and risk of gestational diabetes among women of South Asian and Chinese ethnicity: a population-based study

BMI and BMI change following incident type 2 diabetes and risk of microvascular and macrovascular complications: the EPIC-Potsdam study

Lower insulin clearance is associated with increased risk of type 2 diabetes in Native Americans

Maternal obesity during pregnancy leads to adipose tissue ER stress in mice via miR-126-mediated reduction in Lunapark

Sodium–glucose cotransporter 2 inhibitors reduce myocardial infarct size in preclinical animal models of myocardial ischaemia–reperfusion injury: a meta-analysis

Poor glycaemic control is associated with increased risk of neurodevelopmental disorders in childhood-onset type 1 diabetes: a population-based cohort study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials